Receptor crosstalk is an emerging and recurrent theme in cytokine and growth factor signaling; however, insight into the mechanism(s) underlying these interactions remains limited. Recently, we reported that crosstalk occurs between ErbB3 and the interferon alpha (IFN-a) signaling complex in the myeloma cell line KAS-6/1 and that this crosstalk contributes to the regulation of cell proliferation. In this study, we examined the mechanism underlying the transactivation of ErbB3 in the IFN-a growth-responsive KAS-6/1 cells. The examination of IFN-a receptor 1 and 2 (IFNAR1 and IFNAR2) levels revealed that the KAS-6/1 cell line overexpresses IFNAR1 relative to other myeloma cell lines that are growth arrested by IFN-a. Subsequent investigation of Tyk2, which is constitutively associated with IFNAR1, demonstrated that Tyk2 activation is uniquely sustained in the KAS-6/1 cell line following IFN-a stimulation. Interestingly, silencing of Tyk2 expression via siRNA resulted in attenuation of ErbB3 transactivation. However, inhibition of Jak1 expression also decreased IFN-ainduced tyrosine phosphorylation of ErbB3. Finally, siRNA downregulation of Tyk2 and Jak1 was found to decrease IFN-a-stimulated proliferation. These findings validate our previous report of ErbB3 involvement in IFNa-induced proliferation and further suggest that both Janus kinase members, Tyk2 and Jak1, play a role in the transactivation of ErbB3 in this model system.
Introduction
Signal transduction pathways have classically been described as a linear sequence of events that involve the interaction of a ligand with a specific receptor, activation of a particular signaling cascade(s) and the resulting biological response (Dumont et al., 2001) . However, over the last decade it has become clear that this process may be much more complex than initially anticipated. In fact, numerous reports have now shown that biological responses may be brought about through receptor crosstalk or the transactivation of additional and often unrelated receptor subtypes (reviewed by Hill, 1998) . For example, in rat hepatocytes binding of growth hormone (GH) to its receptor was shown not only to result in the activation of the GH receptor but also in the tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) (Yamauchi et al., 1997) . Interestingly, Jak2 appeared to play a role in the transactivation of the EGFR following GH stimulation. In addition, the phosphorylation of the EGFR was also shown to be required for GH-induced activation of the MAP kinase pathway.
During tumorigenesis and/or tumor progression, malignant cells frequently overexpress or acquire atypical expression of one or more signaling receptors. Given the fact that a variety of receptors have now been shown to be able to act in a nonlinear fashion, receptor crosstalk has emerged as a potential mechanism by which tumor cells may potentially amplify and/or diversify their responses to growth factors/cytokines . To acquire an understanding of growth and survival control in malignant cells, it is therefore imperative to comprehend fully linear as well as potential nonlinear interactions in transformed cells.
In this regard, we have had a long-standing interest in the growth regulation of multiple myeloma (MM), a typically fatal plasma cell malignancy. Thus, we have been actively investigating the ability of the tumor cells in this disease to signal in a nonlinear fashion. More specifically we have had a particular interest in determining if receptor crosstalk plays a role in the ability of IFN-a to modulate myeloma cell growth in a variable manner (Brenning et al., 1985; Jourdan et al., 1991; Westendorf et al., 1996; Jelinek et al., 1997) . Recently, we reported detection of ErbB3, a member of the ErbB family member, on the MM cell line KAS-6/1, which is growth responsive to IFN-a. Based on the fact that ErbB family members are known to play an important role in several cancers (i.e. breast, prostate) and that various ErbB members have previously been suggested to be potentially involved in the development and progression of a subset of B-lymphoblastic leukemias and MM (Buhring et al., 1995; Klein, B., 2003, personal communication) , we were interested in determining if ErbB3 may play a role in the growth regulation of the KAS-6/1 cell line. Interestingly, we discovered that crosstalk occurs between the atypically expressed ErbB3 molecule and the IFN-a receptor in these cells. Furthermore, we were also able to demonstrate through siRNA-mediated downregulation of ErbB3 that this crosstalk does indeed contribute to the IFN-a-induced proliferative ability of these cells .
Despite the abundance of evidence supporting the incidence and importance of receptor crosstalk, few studies have thoroughly examined the mechanism by which receptor crosstalk is facilitated. However, based on our knowledge of receptor signaling and previous receptor crosstalk reports, we hypothesized that there are at least two mechanisms by which receptor crosstalk most likely occurs. These mechanisms include direct physical association of the receptors and/or lateral signaling by nonreceptor tyrosine kinases. As we were previously unable to detect a physical association between ErbB3 and the IFN-a receptor , we hypothesized that crosstalk must be mediated via lateral signaling by nonreceptor tyrosine kinases.
Similar to other cytokine receptors, the type I IFN receptor is devoid of any intrinsic kinase activity (Novick et al., 1994) . However, this deficiency is overcome through utilization of the Jak-STAT pathway, which is comprised of a family of cytoplasmic nonreceptor tyrosine kinases called the Janus kinases (also known as Jaks) and a family of SH2 domain containing proteins called signal transducers and activators of transcription (STATs) (reviewed in Boundy and Kovarik, 2002) . Briefly, ligand binding induces transphosphorylation and activation of Janus kinase family members Tyk2 and Jak1, which are constitutively associated with the a and b subunits of the IFN signaling complex, respectively. Activated Tyk2 and Jak1 then rapidly phosphorylate specific tyrosine residues on the receptor subunits allowing these phosphorylated residues to serve as docking sites for members of the STAT family. Following docking to receptors, the STAT proteins are phosphorylated by Tyk2 and Jak1 allowing homo-or heterodimerization, and subsequent translocation to the nucleus where they regulate the transcription of IFN-responsive genes.
As Jak2 was previously shown to mediate crosstalk between the GH receptor and the EGFR (Yamauchi et al., 1997) and because IFN-a stimulation activates the nonreceptor tyrosine kinases Tyk2 and Jak1, we hypothesized at the outset of this study that either one or both of these kinases are potentially involved in mediating IFN-a-induced crosstalk. Indeed, in the present report we demonstrate that crosstalk between ErbB3 and the IFN-a receptor signaling complex is mediated by both Tyk2 and Jak1.
Materials and methods

Cell lines, culture medium and reagents
The myeloma cell lines ANBL-6, DP-6, KAS-6/1, and KP-6 were derived from primary patient myeloma cells and all have been described previously (Westendorf et al., 1996; Jelinek et al., 1997) . These cell lines were maintained as previously described (Arora et al., 1999) . Recombinant purified IFN-a2b (Schering, Kenilworth, NJ) was used at 10 000 U/ml in immunoprecipitation experiments and at 1000 U/ml in DNA synthesis assays. Interleukin-6 (IL-6) (Novartis Pharma, Basel, Switzerland) was used at 1 ng/ml in DNA synthesis assays. 
Immunofluorescence analysis
Immunoprecipitation and immunoblotting
Cells were cultured in IL-6-free medium supplemented with 0.5% BSA prior to IFN-a addition. Cells (1.0-2.0 Â 10 7 ) were lysed using RIPA lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 1 mM EDTA, 15 mM sodium molybdate, 1 mM NaF) or Brij lysis buffer (10 mM Tris pH 7.4, 150 mM NaCl, 0.5 mM CaCl 2 , 0.5 mM MgCl 2 , 1% Brij-97) supplemented with protease inhibitors (10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml pepstatin, 2 mM Na 3 VO 4 , and 1 mM PMSF). Lysates were cleared of insoluble material by centrifugation for 10 min at 14 000 r.p.m. Following centrifugation, 1 mg/ml of protein-specific antibody (Jak1 or Tyk2; BD Biosciences, San Jose, CA, USA; ErbB3 or IFNAR1; Santa Cruz, CA, USA) bound to protein-A or gammabind-G sepharose beads was added to lysates containing equal amounts of protein. The lysate and immunecomplexes were then incubated with agitation for 2-4 h at 41C. The resulting immunoprecipitates were then washed three times and resuspended in 25 ml of 2 Â SDS loading buffer, heated to 1001C for 5 min, resolved by SDS-PAGE and transferred to Immobilon-P membranes (Millipore Corp., Bedford, MA, USA) for immunoblotting. Membranes were blocked in 25 mM Tris-HCl (pH 7.2), 150 mM NaCl, 0.2% Tween (TBST) supplemented with 0.2% BSA for 1 h. Phosphotyrosine (ptyr) status was detected using an anti-ptyr 4G10 Ab (Upstate Biotechnology, Inc., Lake Placid, NY, USA). The secondary Ab was HRP-conjugated polyclonal anti-mouse IgG (Amersham, Piscataway, NJ, USA). Total ErbB3 was detected using an ErbB3 Ab (Santa Cruz, CA, USA) and a secondary anti-rabbit IgG-HRP Ab (Amersham, Piscataway, NJ, USA). Total Jak1 and Tyk2 were detected using a Jak1 or Tyk2 Ab, respectively (BD Biosciences, San Jose, CA, USA). The secondary Ab used was an HRPconjugated polyclonal anti-mouse IgG (Amersham, Piscataway, NJ, USA). Immunoreactive proteins were detected using an enhanced chemiluminescence detection system (Super Signal, Pierce) and autoradiography. The densitometric analysis was performed using AMBIS analysis software.
siRNA transfection parameters
Transfection of the siRNA duplexes was achieved via electroporation as previously described (Walters and Jelinek, 2002) . The ErbB3 siRNA duplex (target 5 0 AACCAATACC AGACACTGTAC3 0 ), scrambled siRNA duplex (target 5 0 GCGCGC TTTGTAGGATTCG3 0 ) and Smart Pool Jak1 and Tyk2 siRNA duplexes (target sequences are proprietary) were all synthesized and purchased from Dharmacon Research, Inc. (Lafayette, CO, USA).
DNA synthesis assays
Cells were washed twice prior to culture (2.5 Â 10 4 cells/well in a final volume of 200 ml) in 96-well flat bottom microtiter plates (Costar, Cambridge, MA, USA). Cultures were performed in triplicate in the presence of 0.5% BSA, IL-6 (1 ng/ml) and/or IFN-a (1000 U/ml) for 3 days at 371C in the presence of 5% CO 2 . At 48 h following culture initiation, cells were pulsed with 1 mCi tritiated thymidine ( 3 H-TdR; 5.0 Ci/mmol, Amersham, Piscataway, NJ, USA). After 18 h, cells were harvested and 3 HTdR incorporation was assessed using a Beckman scintillation counter.
Results
Differential myeloma cell responsiveness to IFN-a and the potential role of ErbB3
We have previously reported that the IL-6-dependent KAS-6/1 myeloma cell line grows in response to IFN-a (Jelinek et al., 1997) , whereas other IL-6-dependent myeloma cell lines, such as ANBL-6, are growth arrested by IFN-a ( Figure 1a) . Given that MM patients treated with IFN-a also display variable in vivo responses, with unexpected tumor cell growth stimulation observed in some cases (Blade et al., 1991; Sawamura et al., 1992) , we have been investigating the mechanism(s) underlying myeloma cell variability in IFN-a responsiveness. In this regard, we recently reported that IFN-a stimulation of the KAS-6/1 cell line results in transactivation of ErbB3, which is atypically expressed in this cell line, and that IFN-a stimulation results in activation of both the IFN-aR, as well as ErbB3 (Figure 1b) . Additional work using siRNA directed at ErbB3 demonstrated that the inhibition of ErbB3 expression attenuated the IFN-ainduced growth response in the KAS-6/1 cell line . The goal of the present work, therefore, was to investigate the mechanism by which the ligand-activated IFN-aR is able to transactivate ErbB3.
KAS-6/1 cell line overexpresses IFNAR1
Knowing that receptor overexpression can itself lead to signal transduction modifications (DiGiovanna et al., 2002; Kuhn et al., 2003; Long et al., 2003) , especially in malignant cells, we first determine if expression levels of IFNAR1 and IFNAR2 vary between MM cell lines that are growth responsive to IFN-a and those that are growth suppressed by IFN-a. Thus, the KAS-6/1 cell line and three additional MM cell lines were stained with receptor-specific Abs for IFNAR1 and IFNAR2 and analysed by flow cytometry. As shown in Figure 2 , the levels of IFNAR2 are fairly comparable among the cell lines. By contrast, the level of IFNAR1 is much greater in the KAS-6/1 cell line relative to the other cell lines.
Myeloma cell expression levels of Jak1 and Tyk2
Given that Tyk2 has been demonstrated to be constitutively associated with IFNAR1 (Colamonici et al. 1994a, b) and that levels of Tyk2 have been shown to control the stable expression of IFNAR1 (Ragimbeau et al., 2003) , we next examined the levels of Tyk2 expression in the KAS-6/1 cell line as compared to the other MM cell lines. As a control, we also examined the levels of Jak1 expression, which is known to be constitutively associated with IFNAR2. As shown in Figure 3 , the level of expression of both Tyk2 and Jak1 from equal numbers of cells is essentially comparable (b) KAS-6/1 cells were stimulated with IFN-a for 5 min prior to lysis and immunoprecipitation of ErbB3 and IFNAR1. The tyrosine phosphorylation status of ErbB3 and IFNAR1 were then assessed using an anti-ptyr Ab. ErbB3 and IFNAR1 were detected using either an ErbB3-or IFNAR1-specific Ab between the cell lines. By contrast, the level of IFNAR1 is significantly greater in the KAS-6/1 cell line and is therefore consistent with our flow cytometry results.
Tyk2 demonstrates prolonged activation kinetics in the KAS-6/1 cell line As previously mentioned, Ragimbeau et al. (2003) reported that IFNAR1 expression is controlled by expression levels of Tyk2. In the discussion of this report, the authors briefly mention the possibility that IFNAR1 may have a reciprocal effect on Tyk2, such that association with IFNAR1 may effect its conformation and/or catalytic activity. This possibility was attractive to us and thus, we then examined whether there is a difference in the activation kinetics of Tyk2 among the MM cell lines. As a control, the activation kinetics of Jak1 was also examined. Interestingly, the activation of Tyk2, as revealed by tyrosine phosphorylation was sustained in the KAS-6/1 cell line, whereas tyrosine phosphorylation of Tyk2 was markedly diminished at 30 min in both the ANBL-6 and KP-6 cell lines (Figure 4a ). By comparison, however, the activation kinetics of Jak1 was comparable among the three cell lines. Prolonged Tyk2 activation kinetics in the KAS-6/1 cell line was confirmed via densitometric analysis and an extended time course examination of Tyk2 phosphorylation kinetics in the KAS-6/1 and the KP-6 MM cell lines (Figures 4b, 5a and b) . These results suggest that increased expression of IFNAR1 in the KAS-6/1 may aid in prolonged activation of Tyk2, but not Jak1, following IFN-a stimulation.
RNAi-induced downregulation of Tyk2 and Jak1 significantly decreases IFN-a-induced phosphorylation of ErbB3 in the KAS-6/1 cell line Given that the activity of Tyk2 appears to be sustained in the KAS-6/1 cell line and that Janus kinases have been shown by other investigators to transactivate unrelated receptor subtypes (Yamauchi et al., 1997) , we next sought to determine whether Tyk2 was involved in the IFN-a-induced transactivation of ErbB3 in the KAS-6/1 cell line. In order to address this question, we transfected the KAS-6/1 cell line with siRNA specifically targeting Tyk2 and then measured ErbB3 transactivation following IFN-a stimulation. In addition, we also transfected cells with Jak1-and ErbB3-specific siRNA or a scrambled siRNA duplex as a control. As shown in Figure 6 , transfection of siRNA specifically targeting Jak1, Tyk2, or ErbB3 resulted in downregulation of the respective proteins but did not effect the expression of 6 cells each were lysed and used to immunoprecipitate IFNAR1, Jak1, and Tyk2 from four MM cell lines. The resulting immune complexes were then resolved by SDS-PAGE. IFNAR1, Jak1, and Tyk2 were detected using IFNAR1, Jak1, and Tyk2 Abs the additional proteins examined. The transfection of the control scrambled siRNA did not effect expression of any proteins. Of particular note, downregulation of Tyk2 and Jak1 significantly decreased the tyrosine phosphorylation status of ErbB3 following stimulation with IFN-a (bottom panel; lanes 4 and 6). These results suggest that both Tyk2 and Jak1 play a role in the transphosphorylation of ErbB3 in the KAS-6/1 cell line. However, it is also possible that only one kinase directly phosphorylates ErbB3, but only following its activation by the other kinase.
Jak1 and Tyk2 are activated in a reciprocal manner
In order to address whether a hierarchical order of activation of Janus kinases occurs in the KAS-6/1 cell line following IFN-a stimulation, we examined the tyrosine phosphorylation status of Jak1 and Tyk2 following downregulation of each kinase. Interestingly, as shown in Figure 7 , downregulation of Jak1 also resulted in decreased tyrosine phosphorylation of Tyk2 (panel 3, lane 4). Similarly, siRNA-mediated downregulation of Tyk2 resulted in decreased tyrosine phosphorylation of Jak1 (panel 1, lane 6). In fact, even though silencing of Tyk2 was not complete (panel 4, lanes 5 and 6) and there was evidence of low-level Tyk2 tyrosine phosphorylation following IFN-a stimulation (panel 3, lane 6), Jak1 activation was completely blocked. From these results, we conclude that there is a reciprocal activation of the Janus kinases in the KAS-6/1 cell line following IFN-a and that activation of Tyk2 is dependent on Jak1 and vice versa. Figure 5 Extended tyrosine phosphorylation kinetics of Tyk2 reveals that activation of Tyk2 is sustained in the KAS-6/1 cell line. (a) Cells were stimulated with IFN-a for 0, 5, 30, 60, 120, or 240 min prior to lysis and immunoprecipitation of Tyk2. The tyrosine phosphorylation status of Tyk2 was then assessed using an anti-ptyr Ab. Tyk2 levels were detected using Tyk2-specific Ab. (b) The tyrosine phosphorylated Tyk2 Western blot was analysed using AMBIS analysis software. The total net pixel counts of the tyrosine phosphorylated Tyk2 bands were examined and are graphically presented The tyrosine phosphorylation status of Jak1 and Tyk2 were then assessed using an anti-ptyr Ab. Jak1 and Tyk2 levels were detected using either a Jak1-or Tyk2-specific Ab. (b) The tyrosine phosphorylated Tyk2 Western blot was analysed using AMBIS analysis software. The total net pixel counts of the tyrosine phosphorylated 135 kDa bands, which correspond to Tyk2, were examined and are graphically presented siRNA-induced downregulation of Jak1 and Tyk2 by siRNA significantly decreases IFN-a-induced proliferation of KAS-6/1 cells Recently, we demonstrated that siRNA-mediated downregulation of ErbB3 in the KAS-6/1 cell line results in a significant decrease in the ability of these cells to proliferate in response to both IFN-a and IL-6 . We next wished to address whether siRNAmediated downregulation of Tyk2 and Jak1, which results in decreased ErbB3 phosphorylation, would also affect the proliferative responsiveness of these cells to IFN-a. Interestingly, both the Tyk2-and Jak1-specific siRNA transfectants showed a striking overall decrease in the magnitude of IFN-a-stimulated 3 H-TdR incorporation as compared to the control scramble siRNA transfectants (Figure 8) . From these data, we conclude that silencing of Jak1 and Tyk2 expression, like the silencing of ErbB3, in the KAS-6/1 cell line significantly reduces the ability of these cells to demonstrate a proliferative response to IFN-a.
Tyk2 and Jak1 do not form a detectable physical complex with ErbB3
In order to gain insight into mechanism by which Tyk2 or Jak1 are able to phosphorylate ErbB3, we next determined whether Tyk2 directly interacts with ErbB3. Thus, we examined whether Tyk2 or Jak1 could be coimmunoprecipitated with ErbB3 and vice versa following IFN-a stimulation. Lastly, we also determined whether we could co-immunoprecipitate the constitutively associated IFNAR1 and Tyk2 and vice versa. As shown in Figure 9 , we failed to detect by immunoprecipitation methods any evidence indicating that Tyk2 or Jak1 could associate with ErbB3 in the presence or absence of IFN-a stimulation. However, we were able to co-immunoprecipitate IFNAR1 with Tyk2 in the presence or absence of ligand (panel 1, lanes 3 and 4) and vice versa (panel 1, lanes 7 and 8). As these proteins are known to be constitutively associated, this suggests that our conditions were capable of capturing physical protein interactions. Consequently, these results suggest that the mechanism underlying Tyk2 and Jak1 transactivation of ErbB3 must occur through a lateral signaling mechanism, which is yet to be identified in greater detail. Figure 6 RNAi-induced downregulation of Jak1 and Tyk2 decreases IFN-a-induced ErbB3 phosphorylation. KAS-6/1 cells were transfected with either a scrambled control siRNA duplex, Jak1-, Tyk2-, or ErbB3-specific siRNA duplex via electroporation. At 48 h post-siRNA-transfection, cells were stimulated with IFN-a for 10 min and then lysed. Tyk2, Jak1, and ErbB3 were then immunoprecipitated using specific Tyk2, Jak1 and ErbB3 antibodies. The resulting immunocomplexes were then electrophoresed and individual membranes were then probed for Jak1 and Tyk2 using Jak1-and Tyk2-specific antibodies. The tyrosine phosphorylation status of ErbB3 was determined using an anti-p-tyr Ab. The membrane was then striped and reprobed for total levels of ErbB3 Figure 7 Jak1 is required for the activation of Tyk2 and vice versa. KAS-6/1 cells were transfected with either a scrambled control siRNA duplex, Jak1-or Tyk2-specific siRNA duplex via electroporation. At 48 h post-siRNA-transfection, cells were stimulated with IFN-a for 10 min and then lysed. Tyk2 and Jak1 were then immunoprecipitated using specific Tyk2 and Jak1 Abs. The tyrosine phosphorylation status of Tyk2 and Jak1 was determined using an anti-p-tyr Ab Figure 8 RNAi-induced downregulation of Jak1 and Tyk2 decreases the KAS-6/1 proliferative response to IFN-a. KAS-6/1 cells were transfected with either a scrambled control siRNA duplex or Jak1-, Tyk2-or ErbB3-specific siRNA duplexes via electroporation. At 48 h post-siRNA-transfection, cells were cultured in media alone (black bars) or were stimulated with IFN-a (diagonal bars) for 3 days before assaying DNA synthesis. Values are representative of the mean of three independent experiments (7s.d.), with each experimental point performed in triplicate
Discussion
In the current study, we investigated the mechanism underlying IFN-a-induced phosphorylation of ErbB3 in the MM cell line, KAS-6/1. Initial analysis revealed that the KAS-6/1 cell line, which grows in response to IFN-a, expresses considerably more IFNAR1 than other MM cell lines, which are growth inhibited by IFN-a. Receptor overexpression is a classic characteristic of malignant cells and can often lead to signal transduction modification. For example, ErbB2, a ligandless member of the ErbB family of receptors, is overexpressed in 20-30% of breast cancer patients (Slamon et al., 1987) . The overexpression of this receptor is then believed to lead to the excess formation of ErbB2 heterodimers (i.e. ErbB1/ ErbB2, ErbB2/ErbB3, ErbB2/ErbB4). The presence of these heterodimers is then thought to result in several consequences, which include; slow ligand dissociation rates, slow receptor internalization rates and hyperactivity of signal transduction pathways (Harari and Yarden, 2000) . Consequently, these cells tend to have greater rates of proliferation. Thus, overexpression of ErbB2 is used as a prognostic indicator in breast cancer patients and is a key target for therapeutic strategies (Slamon et al., 2001) .
With regard to IFNAR1, to our knowledge this is the first report of overexpression of this receptor in a cell line or patient sample. IFNAR1 is one of two components of the IFN-a signaling complex and has been determined to be necessary for the formation of high-affinity receptor signaling complexes. By contrast, the second component, referred to as IFNAR2, is the subunit primarily responsible for ligand binding. However, both receptor components are typically required for complete IFN-a-induced signal transduction, which, as previously described, involves the Jak-STAT pathway. In this regard, both IFNAR1 and IFNAR2 have been shown to be constitutively associated with the Janus kinase members, Tyk2 and Jak1, respectively. Of particular note, Ragimbeau et al. (2003) recently demonstrated that the expression of IFNAR1 essentially depends upon the level of Tyk2 expression. Thus, we investigated whether Tyk2 was overexpressed in the KAS-6/1 cell line as compared to other MM cell lines with lower IFNAR1 expression. Despite the established association between Tyk2 and IFNAR1, Tyk2 was not found to be overexpressed in the KAS-6/1 cell line. We therefore speculate instead that the increased expression of IFNAR1 may result from mechanisms such as chromosomal translocation, gene amplification, or overexpression of a transcription factor.
Despite the fact that Tyk2 is not overexpressed in the KAS-6/1 cell line, it remains possible that a greater percentage of Tyk2 could be associated or sequestered by IFNAR1 in the KAS-6/1 cell line than in other MM cell lines that do not express high levels of IFNAR1. Of particular note, Dondi et al. (2001) demonstrated that if receptor number exceeds the amount of available Jaks, Jak kinases can be preferentially sequestered by certain receptors. Thus, if a greater percentage of Tyk2 is sequestered to IFNAR1 in the KAS-6/1 cell line, it remains possible that a greater amount of Tyk2 could become activated than in cells that do not overexpress IFNAR1. As a result, the mechanisms responsible for negative regulation of Tyk2 may not be able to maintain the normal transient kinetics of Tyk2 activation, following ligand binding and thus, potentially explain the prolonged activation of Tyk2 in the KAS-6/1 cell line.
While Tyk2 activation appeared to be sustained in the KAS-6/1 cell line, our siRNA-mediated investigation of whether Janus kinases are involved in the IFN-ainduced ErbB3 phosphorylation revealed that silencing of Tyk2 and Jak1 both result in decreased phosphorylation of ErbB3. Consequently, we hypothesized that either or both kinases were involved in IFN-a-induced ErbB3 phosphorylation or that the activation of one kinase was dependent upon the other. Of note, the mechanism of transphosphorylation or the order of activation of the Jak kinases following ligand binding has not been precisely determined for all cytokine receptors. However, it has been hypothesized that this process occurs in a hierarchical fashion. Indeed, with regard to the IFN-a receptor, Krishnan et al. (1997) demonstrated via dominant-negative constructs that there is a hierarchical order of activation of the Janus kinases following ligand binding and that Jak1 is required for the activation of Tyk2. By contrast, our results (Figure 7 ) demonstrate that the activation of Tyk2 and Jak1 is reciprocal and does not occur in a hierarchical manner. However, it remains possible that the order of activation of Tyk2 and Jak1 following IFNa stimulation may vary among cell lines.
Since our data demonstrated that downregulation of Tyk2 and Jak1 resulted in decreased phosphorylation of ErbB3, we also examined whether the IFN-a-induced proliferation displayed by the KAS-6/1 cell line would also be decreased under these same conditions. Indeed, the downregulation of Jak1 and Tyk2 decreased the overall proliferative response of the KAS-6/1 cells. Interestingly, these results correlate with our initial finding that siRNA-mediated downregulation of ErbB3 inhibits IFN-a-induced proliferation in the KAS-6/1 cell Figure 9 Neither Tyk2 nor Jak1 form a detectable physical complex with ErbB3. KAS-6/1 cells were stimulated with IFN-a for 0 or 10 min prior to lysis and immunoprecipitation of ErbB3, IFNaR1, Jak1, and Tyk2. The membrane was then probed for ErbB3, IFNAR1, Jak1, and Tyk2 using Abs specific to each protein line . Given that we have now demonstrated that Jaks are responsible for activating ErbB3 in the KAS-6/1 cell line, it is enticing to speculate that this event is directly linked to IFN-a-induced proliferation in these cells. To address this question fully, we believe that complete silencing of both Tyk2 and Jak1 would be required in the presence of a constitutively activated ErbB3 molecule. However, at the current time, the knockdown efficiency of transient siRNA transfection has been shown to vary for each particular gene of interest (reviewed in . Furthermore, reported that simultaneous gene knockdown can be complex and that typically lower knockdown levels of each gene are achieved. These results suggest that the RNAi machinery or RNA-induced silencing complex (RISC) may be limiting and that siRNAs may complete for interaction with the complex in these experiments. Indeed, preliminary experiments in our lab attempting to simultaneously knockdown Jak1 and Tyk2 resulted in lower knockdown efficiency of each gene (results not shown).
Investigation into whether Tyk2 and/or Jak1 associate with ErbB3 revealed that neither Tyk2 nor Jak1 formed a physical complex with ErbB3 in either the presence or absence of IFN-a stimulation. However, using our co-immunoprecipitation conditions we were able to detect physical association of Tyk2 with IFNAR1 and vice versa, an established constitutive association. However, it remains possible that Tyk2 and/or Jak1 could associate with ErbB3 under different co-immunoprecipitation conditions. Interestingly, Olayioye et al. (1999) demonstrated that Jak2 constitutively associates with ErbB1 and ErbB2 in A431 cells.
Hence, these results suggest that a physical association between ErbB family members and Jak proteins is plausible. Furthermore, in regard to whether Tyk2 and/ or Jak1 are capable of phosphorylating ErbB family members, as previously mentioned, Yamauchi et al. (1997) demonstrated that Jak2 was responsible for mediating GH-induced activation of ErbB1. However, we acknowledge the fact that other proteins have been shown to associate with Janus kinase members (e.g., Fyn) (Uddin et al., 1997) and may potentially play a role in IFN-a-induced crosstalk with ErbB3 and consequently, are currently under investigation. Finally, we also believe that it would be of interest to identify the tyrosine residues that become activated on ErbB3 following IFN-a stimulation, as identification of these residues may reveal which signaling pathways become activated and contribute to the role of ErbB3 in IFN-ainduced proliferation. This information may be of use in suggesting potential future therapeutic targets.
In conclusion, the body of literature regarding the ability of unrelated receptor subtypes to act in a nonlinear fashion or crosscommunicate continues to expand. However, few studies have focused on examining the mechanism underlying this phenomenon. In this regard, our current study provides additional evidence implicating the ability of members of the Janus kinase family to facilitate receptor crosstalk, thereby altering the nature of the downstream response, for example, in this case, conversion of a growth inhibitory response into a growth stimulatory response.
